Related Experiment Video
Updated: Jun 12, 2026
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Experience of gemcitabine plus oxaliplatin chemotherapy in patients with advanced biliary tract carcinoma
Antoine Hollebecque1, Olivier Bouché, Olivier Romano
1Department of Medical Oncology, University Hospital, Lille, France.
Backgrounds:
The combination gemcitabine-oxaliplatin (GEMOX) is frequently used in patients with advanced biliary tract carcinoma (BTC). However, this is only based on phase II studies performed in selected patients.We assessed the efficacy and safety of the GEMOX regimen in non-selected patients with advanced BTC.
Methods:
All consecutive patients with advanced BTC received the GEMOX regimen in a setting outside a study: gemcitabine 1,000 mg/m(2) on day 1, and oxaliplatin 100 mg/m(2) on day 2, treatment repeated every 2 weeks until progression or unacceptable toxicity.
Results:
Forty-four patients were enrolled.
Efficacy:
1 complete and 6 partial responses (objective response rate = 16.3%), 18 tumour stabilizations (41.9%, disease control rate = 58.1%), median progression-free survival was 5.0 months and median overall survival was 11.0 months.
Toxicity:
grade 3 neuropathy in 4 patients, grade 3 asthenia in 5 patients.
Conclusion:
The GEMOX combination was well tolerated, with a modest activity in non-selected patients with advanced BTC. This regimen should be compared to the new standard gemcitabine-cisplatin combination.
